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Abstract
Type 1 diabetes (T1D) is a form of diabetes mellitus resulting from the lack of insu‐
lin secretion by the pancreatic beta cells and which accounts for approximately 5%
of the total number of patients with diabetes worldwide. T1D is one of the most
common endocrine disorders of children, and its incidence is steadily increasing.
T1D is largely considered an autoimmune disorder resulting from the specific de‐
struction of the pancreatic beta-cells that produce insulin. However, T1D patho‐
physiology is still not completely understood, and although insulin and other
therapies ameliorate the manifestations of the disease, no cure is currently available.
Traditionally, T1D has been thought of as a condition of cellular adaptive immuni‐
ty, but evidence exists that components of the innate immune system, such as Toll-
like receptors (TLRs), play a critical role in T1D development. TLRs have a central
role in sensing microbial infections as well as endogenous alarm signals and trigger
the release of inflammatory cytokines. The involvement of these receptors in the
pathophysiology of several chronic diseases has become a major research interest,
and in the last two decades, many studies have suggested the involvement of the
innate immune system in the mechanism triggering T1D. Furthermore, microvascu‐
lar complications in diabetic patients result in considerable morbidity, particularly
diabetic nephropathy, retinopathy, and atherosclerosis. A hallmark of diabetic vas‐
cular pathology is inflammation and endothelial dysfunction. Recent literature sug‐
gests that TLR signaling is involved in vascular inflammation and endothelial
dysfunction and that TLR activation may play a crucial role in diabetic microangi‐
opathy. However, the mechanisms by which TLRs and their ligands contribute to
T1D are not yet clear, and further investigation is needed. The goal of the present
chapter is to address the contribution of TLRs to the mechanisms leading to the de‐
velopment and progression of T1D and to review current possibilities of targeting
TLRs to forestall diabetic complications.
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1. Introduction
The innate immune system is the first line of defense against invading organisms and other
dangerous events in our body. Unlike the acquired immune system, innate immunity identifies
the presence of harm via pattern recognition receptors (PRRs). Toll-like receptors (TLRs) are
one of the most important classes of PRRs for sensing harmful signals. TLRs can recognize two
types of molecules: (1) conserved pathogen molecules such as lipopolysaccharide (LPS),
proteins, and nucleic acids expressed by microbes, viruses, bacteria, and fungi, which are
known as pathogen-associated molecular patterns or PAMPS [1-2] and (2) endogenous
molecules released from damaged cells or tissues such as HMGB-1, HSP60, and C-reactive
protein called damage-associated patterns or DAMPS [3]. To date, ten TLRs have been
identified in humans (TLR1–TLR10) and twelve in mice (TLR1–TLR9 and TLR11–TLR13). Most
TLRs are located on the cell surface, except for TLR3, TLR7, TLR8, and TLR9, which are
expressed in the intracellular compartment, the endosome [4].
All  TLRs share  their  intracellular  domain with the interleukin-1-receptor  (IL-1R)  family.
Two major intracellular signaling pathways are triggered by TLRs, one that is  canonical
and  dependent  on  myeloid  differentiation  primary  response  protein  88  (MyD88)  and
another that is noncanonical and MyD88-independent (Figure 1) pathway. MyD88 binds to
TLRs upon activation and is essential for the induction of inflammatory cytokines via TLRs.
All TLRs, except TLR3, can activate a MyD88-dependent pathway, which involves mitogen-
activated  kinases  and leads  to  the  transcription  of  pro-inflammatory  genes  through the
activation  of  nuclear  factor  κB  (NF-κB).  TLR3  activates  the  TRIF-mediated  pathway,  a
MyD88-independent pathway that in turn activates interferon regulatory factor 3 (IRF-3),
inducing the expression of  interferons (IFNs)  [5].  TLR pathway activation results  in  the
activation  of  the  inhibitor  of  NF-κB  kinase  (IKK)  complex  and  the  transcription  factor
nuclear factor κB (NF-κB). NF-κB has been extensively studied as a regulator of inflamma‐
tory mediators, including tumor necrosis factor alpha (TNF-α). Increased levels of interleu‐
kin 1 beta (IL-1β) and TNF-α have been correlated with an expression of TLR2 and TLR4
on monocytes from T1D patients [6] (Figure 1).
Type 1 diabetes (T1D) is a disease in which the pancreatic insulin-producing beta-cells are lost
or destroyed, usually via autoimmune mechanisms. Consequently, slow and progressive islet
beta-cell impairment and total loss of insulin secretion are observed [7-8]. How the disease is
triggered is unknown; however, research in animal models of T1D supports the hypothesis
that microbial infection and/or innate immune system activation play an important role in
disease mechanisms [9]. Several lines of evidence suggest that T1D progression is strongly
heritable [10-11]. However, in addition to genetic factors, environmental factors such as
chemicals, infections, and components of early childhood diet might contribute to T1D onset
[12]. The development of T1D can be classified into two stages. In the first stage, called insulitis,
Langerhans islets in the pancreas are progressively infiltrated by cells of the immune system,
especially T cells and macrophages (Figure 2). In the second stage, most beta-cells are destroyed
by the infiltrating immune cells. Apoptosis of pancreatic beta-cells is the last step in the initial
pathogenesis of T1D [13]. Regardless of the progress toward the last step of T1D development,
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the initial step, triggering anti-islet autoimmunity, is still unclear and this is one of the most
relevant issues in the field of autoimmune diseases.
Generally, TLR-expressing innate immune cells trigger the initial actions against dangerous
signals, which later lead to the activation of T and B cells of the adaptive immune system.
Although the primary function of TLRs is linked to the innate immunity, there are no reasons
why TLRs may not have a direct function on adaptive immunity, and it has been recently
demonstrated that TLRs are also expressed not only in cells from the innate immune but also
in T and B cells [14-16]. Continuous release of DAMPs from damaged cells and tissues may
maintain the activation of the innate immune system in diseases with long-term low-level
inflammation. Therefore, the participation of innate immunity via TLRs not only in acute but
also in chronic disease has been recently speculated in the literature. The expression of TLRs
in T or B cells has been suggested to provide a cell intrinsic mechanism for innate signals
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Figure 1. Ten human TLRs and their pathways. Signaling pathways activated by TLRs might be MyD88 dependent or
independent. MyD88 is an adaptor molecule, which recruits IRAK and induces phosphorylation. IRAK associates with
TRAF6 or TRAF3, leading to the activation of IKK complex or MKKs and resulting in the activation of NF-κB and other
important transcription factors (CREB and AP1). The activation of a MyD88-dependent pathway leads to induction of
inflammatory cytokines or type I interferons (IFNs). All TLRs, except TLR3, can activate MyD88. The MyD88-inde‐
pendent pathway is called TRIF-mediated pathway (TIR-domain-containing adaptor inducing an NF-κB). TLR4 can al‐
so utilize the TRIF-related adaptor molecule (TRAM) for the activation of NF-κB. In order to switch signaling from
MyD88 to TRIF, TLR4 moves from plasma membrane to the endosomes. Little is known about TLR10 and its ligands,
but this receptor may heterodimerize with TLR1 and TLR2. The activation of TLRs especially TLR2 and TLR4 path‐
ways leads to complications that are associated with the pathogenesis of diabetes. CRBE: cyclic AMP-responsive ele‐
ment binding-protein; AP1: activator protein 1.
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regulating adaptive immune responses [3, 16], which suggest the TLR-mediated activation of
innate immunity may be controlling chronic disorders. However, the exact role of the innate
immunity and TLRs in chronic diseases such as T1D is still under discussion.
TLRs play a major role in the development of several pancreatic diseases [17]. In the last decade,
the involvement of the innate immune system in diabetes development and complications has
been highlighted and investigated by many authors [18-19]. The idea that the initial event in
the pathogenesis of autoimmune T1D comprises sensing of molecular patterns from apoptotic
beta cells by TLRs has been suggested in recent papers [8, 20]. In T1D, necrotic beta-cells might
stimulate dendritic cells (DCs), which are essential in defending against microbial infections
and are involved in initiating and regulating immune responses linked to inflammation [21].
In addition, during the development of T1D, multiple interactions occur between DCs,
macrophages, natural killer cells (NKs), and lymphocytes. Ultimately, the activation of these
cells leads to induction of inflammatory genes [22]. A proinflammatory state is characteristic
of T1D and is manifested by elevated circulating and cellular biomarkers such as augmented
plasma levels of C-reactive proteins (CRP), cytokines (IL-1B, TNF, and IL-6), soluble cell
protein adhesion, chemokines, etc. These increases are further accentuated in T1D patients
with vascular complications [23-24].
Of the various TLRs, TLR2 and TLR4 have an important role in inflammation associated with
diabetes. In addition, T1D harbors a considerably elevated risk for progressive atherosclerotic
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Figure 2. Involvement of TLR2 and TLR4 in the development of T1D. TLR2 and TLR4 on islet beta-cells senses expres‐
sion changes in DAMPS such as HMGB1 and contribute to the initiation of T1D. Activation of TLR2 and TLR4 leads to
NF-κB activation and pro-inflammatory cytokines production, which play a part in T1D inflammatory process and
possibly endothelial dysfunction resulting in diabetic vascular complications. In addition, in T1D, the pancreas is pro‐
gressively infiltrated by cells of the immune system such as macrophages and B-cells which express TLR2 and TLR4.
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events and TLRs may be involved, but the mechanistic basis for this phenomenon is not
completely clear. Likewise, TLRs are involved in the pathogenesis of diabetic microvascular
alterations [25]. However, the TLR activation in this diabetic condition and its association with
vascular or endothelial dysfunction has not been well characterized. Experimental studies
have shown that TLR2 and TLR4 could be important participants in the progression of
atherosclerosis in diabetes [6, 26-27]. On the other hand, TLR3, TLR7, and TLR9 seem to be
involved in the initiation of TD1 [5, 28].
In this chapter, based on the recent advances in understanding the role of the innate immune
system in chronic disease, we focus on the contribution of TLRs to the mechanisms that trigger
T1D onset and the development of its complications. This information might provide new
insights into possibilities for therapeutic intervention by targeting and modulating the
immune system to abrogate or prevent T1D.
2. Contribution of TLRs in the pathogenesis of T1D
Recently, it has become evident that the dysregulation of the innate immune system can
precipitate autoimmune diseases, including T1D. Given its essential role in orchestrating
innate immune responses, the TLRs may be expected to play a significant role in the T1D
development, progression, and its complications. The connections among inflammation,
hyperglycemia, and diabetes have clear implications for the immune system. In addition, TLRs
activate two types of downstream signaling pathways that lead to the activation of NF-κB with
concomitant increase in inflammatory cytokine secretion (Figure 1). Both pathways contribute
significantly to the pathophysiology of inflammation in endothelial dysfunction and are
relevant to diabetic microangiopathy. Therefore, the key point regarding the involvement of
TLRs in T1D and its complications seems to be the inflammatory process.
2.1. TLR2 and TLR4
The activation of the innate immune system via TLRs, in particular, TLR2 and TLR4, seems to
play an important role in the development of T1D. Many authors proposed the sensing of
DAMPs released from damaged pancreatic β-cells by TLR2 to be first event in the development
of T1D [29-30]. The Increased expression of TLR2 and TLR4 in monocytes was described in
patients with T1D compared to healthy patients [6]. In addition, the expression of TLR2 is
augmented in T1D in both rat and human kidneys and has been associated with vascular
complications [31]. Furthermore, T1D patients with microvascular complications showed
increases in TLR2 and TLR4 activity in monocytes compared with matched controls [25]. The
higher expression of TLR2 and TLR4 is associated with poor glycemic control, while the
knockdown of both TLR2 and TLR4 resulted in a 76% decrease in a high glucose-induced NF-
κB response, suggesting an additive effect [32-33]. Also, it has been demonstrated that deletion
of TLR2 in mice significantly abrogates the proinflammatory state of T1D for up to 14 weeks
in mice and improves the wound healing process, supporting a role for TLR2 in promoting
inflammation in diabetes [30, 34].
The Innate Immune System via Toll-Like Receptors (TLRs) in Type 1 Diabetes - Mechanistic Insights
http://dx.doi.org/10.5772/61925
5
There are ample data supporting an important role for inflammation associated with athero‐
sclerosis in T1D and TLRs may be mediating this process. A recent study demonstrated that
TLR2 and TLR4 mediate inflammatory pathways in endothelial cells exposed to high glucose
[35], although the precise mechanism by which glucose fluctuations mediate inflammation in
endothelial dysfunction is unknown. In apolipoprotein E-/- mice, the deficiency of IP-10
(interferon-gamma-inducible-protein 10) or its receptor (CXCR3) reduces vascular lesion
formation. Also, elevated serum IP-10 levels have been shown in diabetes as well as increased
monocytic IP-10 in T1D patients, but it is unclear if the patients had complications [36]. TLR4
agonists such as LPS have been shown to induce IP-10 production, and it has been demon‐
strated that down-regulation of TLR2 and TLR4 abrogates high glucose-induced IP-10 release
via NF-κB inhibition [32].
Although many studies have highlighted the involvement of TLRs in the pathogenesis of T1D,
TLRs might also have a beneficial role against T1D. Since the cause of T1D and the mechanisms
involving this condition are not completely elucidated, the contradiction about the role of the
TLRs in T1D could be dependent on the disease stage or how the disease was triggered. T cells,
especially CD4 and CD25 T cells, play an important role in the prevention of autoimmunity.
These cells not only express different TLRs, including TLR2, but are also functionally regulated
directly or indirectly through TLR signaling [37-38]. Recently, it was showed that treatment of
prediabetic mice with a synthetic TLR2 agonist diminished T1D and increased the number and
function of CD4 and CD25 T cells, also conferring DCs with tolerogenic properties, suggesting
that TLR2 signaling improves immunoregulation to prevent T1D [39]. On the other hand,
another study suggested that TLR2 and MyD88 was dispensable for development of T1D in
non obese diabetic (NOD) mice [40], which exhibit a susceptibility to spontaneous develop‐
ment of autoimmune insulin-dependent diabetes mellitus. NOD mice are a well established
model of autoimmune diseases, including human T1D [41]. These data contrast with other
reports showing the involvement of TLR2 in the initiation of autoimmune responses directed
against beta-cells [42].
In NOD mice, the deletion of TLR4 results in acceleration of diabetes onset and immune cell
infiltration of islets [43]. A recent study in the same animal model showed that TLR4 mediates
cardiac lipid accumulation and diabetic heart disease [44]. On the contrary, treatment with a
TLR4/MD-2 specific agonist monoclonal antibody (UT18) in NOD mice not only prevented
T1D but also reversed new T1D onset diagnosed by polyuria, weight loss, and elevated blood
glucose [45]. Supporting these results, an agonistic monoclonal antibody to TLR4/MD-2
reverses the development of diabetes in a high percentage of NOD mice. TLR4 antibody
treatment increases T regulatory cell numbers in both the periphery and the pancreatic islet,
suggesting a novel immunological tool for management of T1D in humans [46]. Taken
together, these observations suggest a potential role for TLR2 and TLR4 in the pathology of
diabetes. However, the mechanistic details need to be better investigated. Undoubtedly, the
majority of existing data suggest that TLRs play a part in T1D, mediating T1D development
and its complications, even if it is not clear if this is a beneficial role, a detrimental role, or a
combination of the two.
Major Topics in Type 1 Diabetes6
2.2. Other TLRs and T1D
The role of the TLR pathway in the mechanism of T1D has been intensely investigated in the
last decade, and it is undeniable that these receptors are involved in the pathogenesis of T1D.
However, the majority of the studies are focused on TLR2 and TLR4 and only a few studies
have discussed other TLRs such as TLR1, TLR3, TLR7, and TLR9.
To the best of our knowledge, there is only one study showing that TLR1 may be involved in
the mechanism of diabetes. In this work, a detailed phenotypic analysis of the diabetes-
resistant NOD.C3H-congenic strain 6 was evaluated, and the results suggested that TLR1
pathway is involved in the inflammatory response and the development of T1D controlled by
the Idd6 locus [47].
The TLR3 gene codes for an endoplasmic receptor that recognizes dsRNA and plays an
important role in the innate immune response initiated by viral infection. Although there are
only a few studies reporting a link between T1D and TLR3 gene alterations, polymorphisms
in the TLR3 gene seem to be linked to the risk of T1D. In fact, rs5743313 and rs117221827
polymorphisms were associated with an early age at diagnosis and worse glycemic control
[48]. However, genotypic data on a small population of South Africans of Zulu origin sug‐
gested a weak association of the TLR3 polymorphism C2593T, C2642A, and A2690G with T1D
[49]. The hypothesis that viral infections are involved in T1D is based on epidemiological
studies [50]. One of the major observations that support a role for a viral etiology of T1D is
that in accordance rates for T1D in monozygotic twins are only 50% instead of the expected
100% if the characteristic would be explained only by genetic factors. TLR3 is expressed at high
levels in human and mouse pancreatic beta-cells and antigen-presenting DCs, and this receptor
activates the TRIF-mediated pathway, which in turn activates interferon regulatory factor
(IRF)-3 inducing the expression of IFNs. However, NF-κB may also be activated by TLR3 to
upregulate the production of proinflammatory cytokines [5].
TLR7 stimulation activates DCs and T cells to promote autoimmune diabetes in nonobese
diabetic (NOD) mice. Treatment with IRS661, an antagonist for TLR7, inhibits the activation
of DCs and CD8 T cells, as well as diminishes insulitis and diabetes onset in NOD mice [51].
Daily administration of a specific TLR7 ligand, 1V136, reduces autoimmune disease and
modulates DC function [28]. In addition, treatment with 1Z1, an innate immune modulator
generated by conjugating a TLR7 ligand to six units of polyethylene glycol (PEG), effectively
prevented the clinical onset of hyperglycemia and reduced islet inflammation in NOD mice
[52].
The involvement of TLR9 in T1D has been demonstrated in a rat model (diabetes-resistant
BioBreeding or BBDR), which developed the disease following virus infection. In this study,
disease progression was dependent on TLR9 signaling, leading to the activation of splenic B
cells and bone marrow derived DCs [53]. A recent study investigating DCs subpopulations
and their responses to TLRs stimulation in T1D patients, and their relatives showed increased
TLR9-mediated interferon-alpha production in the first-degree relatives of T1D patients [27].
The Innate Immune System via Toll-Like Receptors (TLRs) in Type 1 Diabetes - Mechanistic Insights
http://dx.doi.org/10.5772/61925
7
3. Contribution of TLRs to T1D complications
Diabetes leads to both microvascular and macrovascular complications. Many studies have
shown increased levels of inflammatory biomarkers that could predispose to vascular
complications. It is undeniable that TLRs are emerging as major factors in many diseases
conditions owing to the activation of signaling pathways leading to the expression of inflam‐
matory mediators and induction of immune responses.
Importantly, members of the TLR family play critical roles in the inflammatory components
of vascular pathologies, including atherosclerosis [54-55], a condition characterized by
inflammation of the vessel wall of the arterial tree. Atherosclerosis is an important vascular
complication and the major cause of morbidity and mortality in diabetic patients [56]. Also,
diabetes itself is a risk factor for atherosclerosis. Despite the fact that type 1 diabetics are at
lower risk for atherosclerotic cardiovascular disease than type 2 diabetics because of the
younger age of the former group, the relative risk is 10 times higher in type 1 diabetics than in
nondiabetics of similar age [57]. Moreover, T1D has been linked with increased intima media
thickness and impaired endothelial function (6), which affects vascular homeostasis leading
to complications in diabetes. Lastly, hyperglycemia is a hallmark of diabetes and the role of
glucose in the pathogenesis of atherosclerosis has been intensely discussed [58].
Devaraj et al. [30] reported on the role of TLR2 in the proinflammatory state in diabetes and
incipient diabetic nephropathy. In TLR2 knockout streptozotocin (STZ)-induced diabetic
animals, these authors observed a significant reduction in the NF-κB activity in peritoneal
macrophages as well as in the release of various pro-inflammatory cytokines such as IL-6 and
IL-8 compared to wild-type diabetic mice. Moreover, TLR2 KO STZ mice showed a significant
decreased in albuminuria compared to WT-STZ, as well as increase in podocyte (epithelial cell
in the kidneys) number, decrease in podocyte effacement, and a decrease in macrophages in
the kidney. This study clearly implicates the TLR pathway in the genesis of a vascular
complication in diabetes and demonstrates greater TLR activity in T1D.
Reactive oxygen species (ROS) formed in the vascular wall target a wide range of signaling
molecules in both endothelium and vascular smooth muscle and contribute to vascular
damage. Vascular dysfunction and remodeling through oxidative damage involves increased
production and/or decreased degradation of ROS. One of the main enzymes implicated in
vascular ROS generation is NADPH oxidase, although the mechanism behind induction of
vascular NADPH oxidase activation in diabetes is less clear [59]. Recently, the role of TLRs in
increased ROS levels in diabetes has been investigated [60-61]. It has been shown that the KO
of the P47phox subunit of NADPH oxidase prevents diet-induced obesity via upregulation of
both TLR2 and TLR4 [61]. A study addressing diabetic retinopathy using human retinal
endothelial treated with high glucose showed that hyperglycemia induces TLR2 and TLR4
activation and downstream TLR signaling mediates augmented inflammation possibly via
ROS [62], suggesting a mechanism by which TLRs could contribute to vascular damage in
diabetes. However, the precise ligands involved in the activation of TLRs by hyperglycemia
are still under investigation, and certainly this information will provide new insight for a role
of TLRs in diabetes-associated vascular complications.
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4. Endogenous ligands (DAMPS) for TLRs in the mechanism of T1D
A large number of endogenous molecules may be potent activators of the innate immune
system via TLRs leading to the release of proinflammatory cytokines from monocytes/
macrophages. Unfortunately, there are limited data on the levels of endogenous ligands of
TLR2 and TLR4 in T1D; however, a significant elevation of some ligands for TLR2 and TLR4
in T2D has been recently found. Overall, S100, fibrinogen, hyaluronan, oxidized LDL, and
advanced glycation end products (AGE) showed increased levels in diabetic conditions and
may work as DAMPS for TLRs [63]. However, high-mobility group box-1 protein (HMGB1),
heat shock proteins (HSPs), and growth arrest-specific 6 protein (GAS6) are the ligands for
TLRs specifically associated with T1D have been highlighted in the current literature.
4.1. HMGB1
HMGB1 was initially identified nearly 30 years ago as a chromatin associated protein that is
important for transcriptional regulation. HMGB1 helps organize DNA and facilitates the
binding of several regulatory protein complexes to DNA [64]. In addition to its role in
transcriptional regulation, HMGB1 has been shown to activate proinflammatory responses
following its release by necrotic or injured cells into the extracellular environment [65]. This
protein may also be actively secreted by monocytes/macrophages. HMGB1 is implicated in the
pathogenesis of a number of diseases associated with inflammation and tissue injury [66], and
recently, many studies have suggested that HMGB1 acts as an inflammatory trigger in
autoimmune diseases working as a DAMP [67]. Although the receptor for advanced glycation
end products (RAGE) was the first HMGB1 receptor to be identified, this interaction alone
could not justify all of the observed effects of HMGB1 [68]. Many relevant reports have shown
that HMGB1 binds not only to RAGE, but also to TLRs [69]. The group of receptors that respond
to HMGB1 is still expanding and includes cell membrane expressed TLR4 and TLR2 and
endosomal TLR3, TLR7, and TLR9 [70].
To date, the main TLRs implicated in HMGB1 signaling are TLR2 and TLR4, although it is
unknown if these receptors are acting independently or together. HMGB1 function is altered
in diabetes, and the signaling systems triggered by this protein are not completely understood.
The levels of TLRs and HMGB1 have been shown to be increased in patients with T1D [71],
and HMGB1 is highly expressed in the cytoplasm of the islets in diabetic mice compared with
nondiabetic controls. Furthermore, HMGB1 has been observed to increase in the cytoplasm of
the islets during the progression of diabetes [72], and the augmented expression of this protein
was observed in the retinas of diabetic patients with retinopathy [73].
HMGB1 polypeptide by itself has a weak proinflammatory activity, but it acquires proinflam‐
matory activity through binding to proinflammatory mediators [74]. It is of interest to note
that high glucose concentrations upregulate HMGB1, a ligand to TLR2 and TLR4 known to
produce inflammation through NF-κB activation in human endothelial cells [69]. A recent
study showed that while infusion of small amounts of glucose results in oxidative and
inflammatory stress in patients with T1D, insulin infusion exerts an anti-inflammatory effect
by suppression of TLRs and HMGB1 in mononuclear cells of T1D patients [75]. Moreover, it
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has been suggested that the activation of TLR4 and RAGE by HMGB1 mediates injury and
inflammation by the activation of NF-κB in response to hyperglycemia [68]. A study using
NOD mice to address the significance of HMGB1 in the natural history of diabetes showed
that HMGB1 interacts with TLR4 in isolated islets. By examining the effects of anti-TLR4
antibodies on HMGB1 cell surfacing binding, the authors suggested that TLR4 is the main
receptor for HMGB1 on beta-cells and that HMGB1 may signal through TLR4 to selectively
impair beta-cells during the progression of T1D [72]. Overall, a considerable body of evidence
suggests that a complex set of mechanisms involving HMGB1, RAGE, and TLRs play a
significant role in the development of chronic inflammation in diabetes [68].
On the other hand, many studies have shown that HMGB1 has angiogenic properties in
promoting endothelial cell sprouting and migration under hypoxic and necrotic conditions
[76-77]. There are data suggesting that release of HMGB1 in wounds initiates TLR4-dependent
responses that contribute to neovascularization [78]. In addition, research on the transcrip‐
tional profiles of angiogenic endothelial cells has revealed HMGB1 as a promising angiogenic
factor [79]. Conversely, a potential role for HMGB1 in atherosclerosis [80] is possible, shown
by increased HMGB1 expression in atherosclerotic lesions compared with normal arteries.
Under some circumstances, HMGB1 may act as a double-edged sword, but it appears that
HMGB1 as a ligand for TLRs in T1D plays a detrimental action. Despite these apparent
conflicting results, HMGB1 has a central role in mediating local and systemic responses to
several stimuli, is involved in TLRs pathways, and may have therapeutic relevance in T1D.
4.2. HSPs
Heat shock proteins (HSPs) were originally identified as a set of proteins that are upregulated
by increases in temperature [81]. These proteins were named for their apparent molecular
weight, for example, HSP70 and HSP60, and have been shown to be among the most highly
conserved proteins in the cell. Some HSPs, like HSP60s, are already abundant proteins that are
further upregulated during stressful conditions. Other HSPs, like HSP70, have homologues
that are constitutively highly expressed (sometimes referred to as HSC70s) and other homo‐
logues that are stress inducible. Most HSPs function as molecular chaperones that assist in the
folding of newly synthesized, misfolded, or damaged proteins. Their requirement in protein
folding helps to explain the important role of HSPs in both stress and nonstress conditions and
the high degree of HSP conservation.
In addition to their primary role in intracellular protein folding, HSPs have been co-opted in
a variety of other pathways. HSPs play an important role in cellular pathways involving
cellular growth, division, and apoptosis. HSPs have also been implicated in various aspects of
immune system modulation [82]. For example, HSPs have been shown to be involved in
antigen presentation through their ability to bind and traffic proteins and peptides.
While their primary function is inside the cell, during stress, HSPs can be expressed on cell
surfaces or secreted. One of their extracellular functions is the cross presentation of various
antigens that they can bind. In addition, extracellular and purified HSP70 and HSP60 have
been shown to bind to TLR2 and TLR4, which results in NF-κB activation in a MyD88 and
CD14-dependent manner [83]. HSPs can activate immune cells, including B cells, NK cells,
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DCs, macrophages, and T cells. However, these results have been somewhat controversial as
some HSP preparations have been shown to be contaminated with bacterial molecules,
including LPS. Nevertheless, the abundance of HSPs, their high level of conservation, and their
roles in cellular stress and inflammation may all help to explain why HSPs have been classified
as important components of DAMP signals.
HSP60 and HSP70 have been implicated as key players in T1D. Both mouse models of T1D
(NOD mice) and human patients have T cells that recognize and are activated by HSP60 and
HSP70 [84-86]. These activated T cells then go to the pancreatic islets and recognize self HSP60
as an autoantigen. Extracellular HSP70 levels are positively correlated with insulin resistance
in vivo and can cause β-cell dysfunction and death in vitro [87]. In mouse models, exogenous
HSP60 and immunogenic peptides from HSP60 have been shown to alter the effects of T cells
and prevent further β-cell destruction [88]. One peptide, in particular, DiaPep277, has shown
promise in phase II clinical trials [89-90]. Phase III clinical trials using this peptide have been
completed, but problems with the data analysis have surfaced and a new analysis of the clinical
data is currently underway and expected to be completed soon [91-92]. HSP60 and HSP70 have
also been implicated in complications of T1D, including atherosclerosis, indicating that they
may have multiple roles in T1D [93-95].
4.3. GAS6
Growth arrest-specific 6 (GAS6) protein is another endogenous ligand of TLR2 and TLR4 that
has been studied in experimental models of diabetic nephropathy [96], which is the most
common cause of end-stage renal diseases, affecting 30% of T1D patients [97]. GAS6 and its
receptor Axl play a key role in the development of glomerular hypertrophy, a hallmark of the
early phase of nephropathy. In diabetic rats, it has been demonstrated that GAS6/Axl mediates
glomerular hypertrophy during diabetes [96]. However, there is a paucity of information about
the association of GAS6 and TLRs, and the involvement of GAS6 as a ligand for TLRs in T1D
is unknown. Recently, analyzing the levels of ligands of TLR2 and TLR4 in mononuclear cells
isolated from blood samples collected in patients with T1D, Deveraj and coworkers showed
increased levels of HSP60 and HMGB1, but no significant difference in the levels of GAS6
between T1D diabetic group and their matched controls [71]. Therefore, further studies are
necessary to clarify if there is a link between GAS6 and TLRs in the pathogenesis of T1D.
5. Targeting TLRs to manage T1D
Studies into the mechanisms behind disease progression have tended focus on identifying the
important cell types and pathways involved in T1D. Definitely, TLR pathways are involved
in T1D, making these receptors a tempting immune-based therapeutic intervention to handle
T1D. TLR2 and TLR4 have a potential role in mediating inflammation and consequently, the
complications associated with diabetes, mainly vascular damage, making them attractive
targets. The deficiency of TLR4 as well as TLR2 is associated with reduced atherosclerosis and
inflammatory state in diabetic mice [30, 98]. Treatment with a TLR4 antagonist was shown to
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inhibit vascular inflammation and atherogenesis in STZ-induced ApoE-/- diabetic mice, as well
as lower serum cholesterol and triglyceride levels in nondiabetic ApoE-/- mice [99]. It has been
shown that TLR9-/- NOD mice present a delay in the onset of diabetes with decreased IFN-α
production and decreased diabetogenic CD8 T cells in pancreatic lymph nodes. Moreover, the
addition of a TLR9 antagonist oligodeoxynucleotide or chloroquine inhibited bone-marrow-
derived DCs activation and CD8 T cells priming in response to CpG, an agonist of TLR9
[100].
Conversely, TLR agonists have been successfully used in NOD mice to delay T1D by inducing
tolerogenic responses [39, 101]. The TLR2 agonist Pam3CSK4, when administered chronically
in NOD mice, inhibits the development of T1D. Also, diabetogenic T cell priming of DCs was
attenuated by chronic treatment with Pam3CSK4, suggesting DC tolerance [20]. Furthermore,
the combination of TLR2 tolerization and inhibition of dipeptydil peptidase 4 (DPP4), which
has been demonstrated to ameliorate STZ-induced diabetes by increasing beta-cell mass [102],
can reverse early-onset diabetes in NOD mice [101].
Briefly, two contradictory possibilities have been considered regarding TLRs as a target to
manage T1D. One is based on the belief that TLRs mediate T1D onset and its complications.
Therefore, targeting these receptors using antibody treatment, pharmacological antagonist, or
genetic approaches could minimize diabetes complications and decrease inflammation. The
second possibility is based on the strategy of inhibiting T1D by tolerance mechanisms. There
are scientific reports for both possibilities, making these receptors an attractive future option
for treatment of T1D. However, the exact role of TLRs in the pathogenesis of T1D is not
completely understood and the initial event of T1D is not revealed. Therefore, therapeutic
approaches for T1D using TLR targeting remain a mere theoretical alternative.
6. Conclusion
The idea that the upregulation of TLR pathways, under some circumstances, leads to the
induction of proinflammatory responses, and islet destruction is consistent with emerging data
in animal models of T1D. In addition, a large body of evidence suggests increased TLR activity
in diabetic patients, and these receptors have been suggested to be involved in the pathogenesis
of diabetic vasculopathies. Therefore, therapeutic strategies to prevent TLR-mediated inflam‐
mation in T1D via modulation of either receptors or their DAMPs ligands can be a welcome
addition to the available approaches to deal with T1D and diabetic vascular complications.
However, targeting TLRs themselves using approaches such as antagonists could pose the risk
of compromising host immunity. In addition, while some antigen-based immunotherapies
targeting TLR ligands have proven to be protective against T1D development in animal
models, these protocols might not be successfully adaptable to human diabetic patients at the
time of diagnosis due to the nature of pathogenic and tolerogenic antigen selection in animal
models and human individuals [103].
In fact, there exist number crucial questions regarding TLRs and T1D mechanisms that remain
to be addressed. One of the major questions is do TLR pathways promote the initiation or
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effector phase of diabetes, or both? A more complete understanding of how the innate immune
system via TLRs can modulate autoimmune responses to beta-cell antigens, as well as the
mechanisms by which these receptors are contributing to triggering and tuning T1D is crucial,
not only because this information can lead to clear elucidation of the role of the innate immune
system in TD1 but also because it may clarify whether TLRs can be used as an innovative
clinical approach to manage or prevent this disease.
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